Patients with a Ruptured Abdominal Aortic Aneurysm Are Better Informed in Hospitals with an "EVAR-preferred" Strategy: An Instrumental Variable Analysis of the Dutch Surgical Aneurysm Audit.
Aged
Aged, 80 and over
Aortic Aneurysm, Abdominal
/ diagnostic imaging
Aortic Rupture
/ diagnostic imaging
Blood Vessel Prosthesis Implantation
/ adverse effects
Clinical Decision-Making
Endovascular Procedures
/ adverse effects
Female
Hospital Mortality
Humans
Male
Medical Audit
Netherlands
Postoperative Complications
/ mortality
Prospective Studies
Risk Assessment
Risk Factors
Time Factors
Treatment Outcome
Journal
Annals of vascular surgery
ISSN: 1615-5947
Titre abrégé: Ann Vasc Surg
Pays: Netherlands
ID NLM: 8703941
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
17
04
2020
revised:
28
05
2020
accepted:
01
06
2020
pubmed:
20
6
2020
medline:
1
12
2020
entrez:
20
6
2020
Statut:
ppublish
Résumé
While several observational studies suggested a lower postoperative mortality after minimal invasive endovascular aneurysm repair (EVAR) in patients with a ruptured abdominal aortic aneurysm (RAAA) compared to conventional open surgical repair (OSR), landmark randomized controlled trials have not been able to prove the superiority of EVAR over OSR. Randomized controlled trials contain a selected, homogeneous population, influencing external validity. Observational studies are biased and adjustment of confounders can be incomplete. Instrumental variable (IV) analysis (pseudorandomization) may help to answer the question if patients with an RAAA have lower postoperative mortality when undergoing EVAR compared to OSR. This is an observational study including all patients with an RAAA, registered in the Dutch Surgical Aneurysm Audit between 2013 and 2017. The risk difference (RD) in postoperative mortality (30 days/in-hospital) between patients undergoing EVAR and OSR was estimated, in which adjustment for confounding was performed in 3 ways: linear model adjusted for observed confounders, propensity score model (multivariable logistic regression analysis), and IV analysis (two-stage least square regression), adjusting for observed and unobserved confounders, with the variation in percentage of EVAR per hospital as the IV instrument. 2419 patients with an RAAA (1489 OSR and 930 EVAR) were included. Unadjusted postoperative mortality was 34.9% after OSR and 22.6% after EVAR (RD 12.3%, 95% CI 8.5-16%). The RD adjusted for observed confounders using linear regression analysis and propensity score analysis was, respectively, 12.3% (95% CI 9.6-16.7%) and 13.2% (95%CI 9.3-17.1%) in favor of EVAR. Using IV analysis, adjusting for observed and unobserved confounders, RD was 8.9% (95% CI -1.1-18.9%) in favor of EVAR. Adjusting for observed confounders, patients with an RAAA undergoing EVAR had a significant better survival than OSR in a consecutive large cohort. Adjustment for unobserved confounders resulted in a clinical relevant RD. An "EVAR preference strategy" in patients with an RAAA could result in lower postoperative mortality.
Sections du résumé
BACKGROUND
BACKGROUND
While several observational studies suggested a lower postoperative mortality after minimal invasive endovascular aneurysm repair (EVAR) in patients with a ruptured abdominal aortic aneurysm (RAAA) compared to conventional open surgical repair (OSR), landmark randomized controlled trials have not been able to prove the superiority of EVAR over OSR. Randomized controlled trials contain a selected, homogeneous population, influencing external validity. Observational studies are biased and adjustment of confounders can be incomplete. Instrumental variable (IV) analysis (pseudorandomization) may help to answer the question if patients with an RAAA have lower postoperative mortality when undergoing EVAR compared to OSR.
METHODS
METHODS
This is an observational study including all patients with an RAAA, registered in the Dutch Surgical Aneurysm Audit between 2013 and 2017. The risk difference (RD) in postoperative mortality (30 days/in-hospital) between patients undergoing EVAR and OSR was estimated, in which adjustment for confounding was performed in 3 ways: linear model adjusted for observed confounders, propensity score model (multivariable logistic regression analysis), and IV analysis (two-stage least square regression), adjusting for observed and unobserved confounders, with the variation in percentage of EVAR per hospital as the IV instrument.
RESULTS
RESULTS
2419 patients with an RAAA (1489 OSR and 930 EVAR) were included. Unadjusted postoperative mortality was 34.9% after OSR and 22.6% after EVAR (RD 12.3%, 95% CI 8.5-16%). The RD adjusted for observed confounders using linear regression analysis and propensity score analysis was, respectively, 12.3% (95% CI 9.6-16.7%) and 13.2% (95%CI 9.3-17.1%) in favor of EVAR. Using IV analysis, adjusting for observed and unobserved confounders, RD was 8.9% (95% CI -1.1-18.9%) in favor of EVAR.
CONCLUSIONS
CONCLUSIONS
Adjusting for observed confounders, patients with an RAAA undergoing EVAR had a significant better survival than OSR in a consecutive large cohort. Adjustment for unobserved confounders resulted in a clinical relevant RD. An "EVAR preference strategy" in patients with an RAAA could result in lower postoperative mortality.
Identifiants
pubmed: 32554198
pii: S0890-5096(20)30516-1
doi: 10.1016/j.avsg.2020.06.015
pii:
doi:
Types de publication
Comparative Study
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
332-344Investigateurs
P J Van den Akker
(PJ)
G J Akkersdijk
(GJ)
G P Akkersdijk
(GP)
W L Akkersdijk
(WL)
M G van Andringa de Kempenaer
(MG)
C H Arts
(CH)
J A Avontuur
(JA)
O J Bakker
(OJ)
R Balm
(R)
W B Barendregt
(WB)
J A Bekken
(JA)
M H Bender
(MH)
B L Bendermacher
(BL)
M van den Berg
(M)
P Berger
(P)
R J Beuk
(RJ)
J D Blankensteijn
(JD)
R J Bleker
(RJ)
J J Blok
(JJ)
A S Bode
(AS)
M E Bodegom
(ME)
K E van der Bogt
(KE)
A P Boll
(AP)
M H Booster
(MH)
B L Borger van der Burg
(BL)
G J de Borst
(GJ)
W T Bos-van Rossum
(WT)
J Bosma
(J)
J M Botman
(JM)
L H Bouwman
(LH)
V Brehm
(V)
M T de Bruijn
(MT)
J L de Bruin
(JL)
P Brummel
(P)
J P van Brussel
(JP)
S E Buijk
(SE)
M A Buijs
(MA)
M G Buimer
(MG)
D H Burger
(DH)
H C Buscher
(HC)
E Cancrinus
(E)
P H Castenmiller
(PH)
G Cazander
(G)
A M Coester
(AM)
P H Cuypers
(PH)
J H Daemen
(JH)
I Dawson
(I)
J E Dierikx
(JE)
M L Dijkstra
(ML)
J Diks
(J)
M K Dinkelman
(MK)
M Dirven
(M)
D E Dolmans
(DE)
R C van Doorn
(RC)
L M van Dortmont
(LM)
J W Drouven
(JW)
M M van der Eb
(MM)
D Eefting
(D)
G J van Eijck
(GJ)
J W Elshof
(JW)
B H Elsman
(BH)
A van der Elst
(A)
M I van Engeland
(MI)
R G van Eps
(RG)
M J Faber
(MJ)
W M de Fijter
(WM)
B Fioole
(B)
T M Fokkema
(TM)
F A Frans
(FA)
W M Fritschy
(WM)
P H Fung Kon Jin
(PH)
R H Geelkerken
(RH)
W B van Gent
(WB)
G J Glade
(GJ)
B Govaert
(B)
R P Groenendijk
(RP)
H G de Groot
(HG)
R F van den Haak
(RF)
E F de Haan
(EF)
G F Hajer
(GF)
J F Hamming
(JF)
E S van Hattum
(ES)
C E Hazenberg
(CE)
P P Hedeman Joosten
(PP)
J N Helleman
(JN)
L G van der Hem
(LG)
J M Hendriks
(JM)
J A van Herwaarden
(JA)
J M Heyligers
(JM)
J W Hinnen
(JW)
R J Hissink
(RJ)
G H Ho
(GH)
P T den Hoed
(PT)
M T Hoedt
(MT)
F van Hoek
(F)
R Hoencamp
(R)
W H Hoffmann
(WH)
W Hogendoorn
(W)
A W Hoksbergen
(AW)
E J Hollander
(EJ)
M Hommes
(M)
C J Hopmans
(CJ)
L C Huisman
(LC)
R G Hulsebos
(RG)
K M Huntjens
(KM)
M M Idu
(MM)
M J Jacobs
(MJ)
M F van der Jagt
(MF)
J R Jansbeken
(JR)
R J Janssen
(RJ)
H H Jiang
(HH)
S C de Jong
(SC)
T A Jongbloed-Winkel
(TA)
V Jongkind
(V)
M R Kapma
(MR)
B P Keller
(BP)
A Khodadade Jahrome
(A)
J K Kievit
(JK)
P L Klemm
(PL)
P Klinkert
(P)
N A Koedam
(NA)
M J Koelemaij
(MJ)
J L Kolkert
(JL)
G G Koning
(GG)
O H Koning
(OH)
R Konings
(R)
A G Krasznai
(AG)
R M Krol
(RM)
R H Kropman
(RH)
R R Kruse
(RR)
L van der Laan
(L)
M J van der Laan
(MJ)
J H van Laanen
(JH)
G W van Lammeren
(GW)
D A Lamprou
(DA)
J H Lardenoye
(JH)
G J Lauret
(GJ)
B J Leenders
(BJ)
D A Legemate
(DA)
V J Leijdekkers
(VJ)
M S Lemson
(MS)
M M Lensvelt
(MM)
M A Lijkwan
(MA)
R C Lind
(RC)
F T van der Linden
(FT)
P F Liqui Lung
(PF)
M J Loos
(MJ)
M C Loubert
(MC)
K M van de Luijtgaarden
(KM)
D E Mahmoud
(DE)
C G Manshanden
(CG)
E C Mattens
(EC)
R Meerwaldt
(R)
B M Mees
(BM)
G C von Meijenfeldt
(GC)
T P Menting
(TP)
R Metz
(R)
R C Minnee
(RC)
J C de Mol van Otterloo
(JC)
M J Molegraaf
(MJ)
Y C Montauban van Swijndregt
(YC)
M J Morak
(MJ)
R H van de Mortel
(RH)
W Mulder
(W)
S K Nagesser
(SK)
C C Naves
(CC)
J H Nederhoed
(JH)
A M Nevenzel-Putters
(AM)
A J de Nie
(AJ)
D H Nieuwenhuis
(DH)
J Nieuwenhuizen
(J)
R C van Nieuwenhuizen
(RC)
D Nio
(D)
V J Noyez
(VJ)
A P Oomen
(AP)
B I Oranen
(BI)
J Oskam
(J)
H W Palamba
(HW)
A G Peppelenbosch
(AG)
A S van Petersen
(AS)
B J Petri
(BJ)
M E Pierie
(ME)
A J Ploeg
(AJ)
R A Pol
(RA)
E D Ponfoort
(ED)
I C Post
(IC)
P P Poyck
(PP)
A Prent
(A)
S Ten Raa
(S)
J T Raymakers
(JT)
M Reichart
(M)
B L Reichmann
(BL)
M M Reijnen
(MM)
J A de Ridder
(JA)
A Rijbroek
(A)
M J van Rijn
(MJ)
R A de Roo
(RA)
E V Rouwet
(EV)
B R Saleem
(BR)
P B Salemans
(PB)
M R van Sambeek
(MR)
M G Samyn
(MG)
H P van 't Sant
(HP)
J van Schaik
(J)
P M van Schaik
(PM)
D M Scharn
(DM)
M R Scheltinga
(MR)
A Schepers
(A)
P M Schlejen
(PM)
F J Schlosser
(FJ)
F P Schol
(FP)
V P Scholtes
(VP)
O Schouten
(O)
M A Schreve
(MA)
G W Schurink
(GW)
C J Sikkink
(CJ)
A Te Slaa
(A)
H J Smeets
(HJ)
L Smeets
(L)
R R Smeets
(RR)
A A de Smet
(AA)
P C Smit
(PC)
T M Smits
(TM)
M G Snoeijs
(MG)
A O Sondakh
(AO)
M J Speijers
(MJ)
T J van der Steenhoven
(TJ)
S M van Sterkenburg
(SM)
D A Stigter
(DA)
R A Stokmans
(RA)
R P Strating
(RP)
G N Stultiëns
(GN)
J E Sybrandy
(JE)
J A Teijink
(JA)
B J Telgenkamp
(BJ)
M Teraa
(M)
M J Testroote
(MJ)
T Tha-In
(T)
R M The
(RM)
W J Thijsse
(WJ)
I Thomassen
(I)
I F Tielliu
(IF)
R B van Tongeren
(RB)
R J Toorop
(RJ)
E Tournoij
(E)
M Truijers
(M)
K Türkcan
(K)
R P Tutein Nolthenius
(RP)
Ç Ünlü
(Ç)
R H Vaes
(RH)
A A Vafi
(AA)
A C Vahl
(AC)
E J Veen
(EJ)
H T Veger
(HT)
M G Veldman
(MG)
S Velthuis
(S)
H J Verhagen
(HJ)
B A Verhoeven
(BA)
C F Vermeulen
(CF)
E G Vermeulen
(EG)
B P Vierhout
(BP)
R J van der Vijver-Coppen
(RJ)
M J Visser
(MJ)
J A van der Vliet
(JA)
C J Vlijmen-van Keulen
(CJ)
R Voorhoeve
(R)
J R van der Vorst
(JR)
A W Vos
(AW)
B de Vos
(B)
C G Vos
(CG)
G A Vos
(GA)
M T Voute
(MT)
B H Vriens
(BH)
P W Vriens
(PW)
A C de Vries
(AC)
D K de Vries
(DK)
J P de Vries
(JP)
M de Vries
(M)
C van der Waal
(C)
E J Waasdorp
(EJ)
B M Wallis de Vries
(BM)
L A van Walraven
(LA)
J L van Wanroij
(JL)
M C Warlé
(MC)
W van de Water
(W)
V van Weel
(V)
A M van Well
(AM)
G M Welten
(GM)
R J Welten
(RJ)
J J Wever
(JJ)
A M Wiersema
(AM)
O R Wikkeling
(OR)
W I Willaert
(WI)
J Wille
(J)
M C Willems
(MC)
E M Willigendael
(EM)
E D Wilschut
(ED)
W Wisselink
(W)
M E Witte
(ME)
C H Wittens
(CH)
C Y Wong
(CY)
R Wouda
(R)
O Yazar
(O)
K K Yeung
(KK)
C J Zeebregts
(CJ)
M L van Zeeland
(ML)
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.